VLON Vallon Pharmaceuticals, Inc. Stock Quote

VLON [NASD]

Index	-	P/E	-	EPS (ttm)	-1.20	Insider Own	0.40%	Shs Outstand	6.81M	Perf Week	21.79%
Market Cap	35.52M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	30.47%	Shs Float	3.20M	Perf Month	8.59%
Income	-7.70M	PEG	-	EPS next Q	-	Inst Own	5.60%	Short Float	2.38%	Perf Quarter	-3.63%
Sales	0.00M	P/S	-	EPS this Y	-38.10%	Inst Trans	-34.69%	Short Ratio	0.11	Perf Half Y	32.75%
Book/sh	1.28	P/B	4.15	EPS next Y	74.60%	ROA	-82.20%	Target Price	12.00	Perf Year	-
Cash/sh	1.38	P/C	3.86	EPS next 5Y	-	ROE	-105.30%	52W Range	3.61 - 10.36	Perf YTD	-29.39%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	435.30%	52W High	-48.75%	Beta	-
Dividend %	-	Quick Ratio	7.60	Sales past 5Y	-	Gross Margin	-	52W Low	47.09%	ATR	1.02
Employees	2	Current Ratio	7.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.94	Volatility	37.76% 19.07%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	-19.30%	Profit Margin	-	Rel Volume	0.87	Prev Close	5.39
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	682.28K	Price	5.31
Recom	2.00	SMA20	4.39%	SMA50	-10.36%	SMA200	0.15%	Volume	590,801	Change	-1.48%

Nov-12-21 08:05AM	Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-11-21 08:05AM	Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event GlobeNewswire +6.26%
Nov-10-21 08:35AM	Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference GlobeNewswire -9.62%
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th ACCESSWIRE +11.82%
Nov-01-21 08:35AM	Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting GlobeNewswire
Oct-26-21 03:23PM	We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully Simply Wall St.
Oct-12-21 08:35AM	Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements GlobeNewswire
Sep-14-21 08:05AM	Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board GlobeNewswire -13.94%
Aug-11-21 08:05AM	Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit GlobeNewswire
Aug-10-21 08:05AM	Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-13-21 08:05AM	Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR GlobeNewswire
May-30-21 04:48AM	Insider Buying: The Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Independent Non-Executive Director Just Bought US$72k Worth Of Shares Simply Wall St.
May-19-21 08:15AM	We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate Simply Wall St.
May-13-21 09:15AM	Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
May-11-21 09:05AM	Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer GlobeNewswire
May-07-21 08:05AM	Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit GlobeNewswire +5.15%
Apr-26-21 09:05AM	Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum GlobeNewswire
Apr-13-21 08:05AM	Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval GlobeNewswire +15.32%
Mar-29-21 08:05AM	Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire +7.03%
Mar-03-21 08:35AM	Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Feb-23-21 09:05AM	Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors GlobeNewswire
Feb-12-21 03:30PM	Vallon Pharmaceuticals Announces Closing of Initial Public Offering GlobeNewswire
Feb-09-21 10:24PM	Vallon Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Leanne M.	Chief Financial Officer	Jun 04	Buy	4.08	1,508	6,153	6,250	Jun 04 04:06 PM
Kelly Leanne M.	Chief Financial Officer	Jun 03	Buy	4.05	1,085	4,394	4,742	Jun 04 04:06 PM
Kelly Leanne M.	Chief Financial Officer	Jun 02	Buy	4.00	3,657	14,628	3,657	Jun 04 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience